Antibody-drug conjugate · Cytotoxic, directed at cadherin-6 (CDH6) · developed by NextCure
SIM0505 is an antibody-drug conjugate in which an anti-CDH6 monoclonal antibody is linked by a cleavable linker to CPT116, a camptothecin derivative. The antibody binds cadherin-6 on CDH6-expressing tumor cells, and the released payload inhibits DNA topoisomerase I, causing DNA breaks and apoptosis. It is being studied in advanced solid tumors, platinum-resistant ovarian cancer, fallopian tube cancer, renal cell carcinoma, uterine serous carcinoma, primary peritoneal cancer and non-small cell lung cancer.
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT06792552 | Phase 1 | Advanced Solid Tumors | Recruiting | NXTC |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Advanced Solid TumorsFallopian Tube CancerNSCLC (Non-small Cell Lung Cancer)Papillary Renal Cell Carcinoma (Prcc)Platinum Resistant Ovarian CancerPrimary Peritoneal CancerRenal Cell Carcinoma (RCC)Uterine Serous Carcinoma (USC)
Updated Oct 25, 2026. Something wrong or missing? Report it on the NXTC page.
See NXTC's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
NXTC catalysts and pipeline →